Letybo (Korean Botox)
LetYbo is a botulinum toxin type A injectable product used for various cosmetic and medical purposes. It works by temporarily paralyzing or weakening targeted muscles, reducing the appearance of wrinkles and fine lines. Unlike Botox and Dysport, LetYbo has unique characteristics that set it apart. The FDA approved LetYbo based on evidence from three clinical trials of 1,271 patients with moderate to severe wrinkles between the eyebrows for efficacy and safety.
LetYbo is primarily used for aesthetic purposes, particularly in the treatment of facial wrinkles and lines, such as frown lines, forehead lines, crow's feet, and bunny lines. It can also be used to lift and contour eyebrows, slim the jawline, and soften neck bands. Store unopened Letybo vials in a refrigerator between 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze.
LetYbo is also utilized for non-surgical procedures such as hyperhidrosis, migraine headaches, and urinary incontinence. While it belongs to the same class of botulinum toxin type A products as Botox and Dysport, it distinguishes itself through its unique formulation and molecular structure. This distinction may result in variations in onset time, duration of effect, and diffusion patterns. Some practitioners and patients report that LetYbo may have a quicker onset of action and longer-lasting results compared to its counterparts. Additionally, LetYbo may offer a more natural and smoother appearance due to its diffusion properties.
LetYbo has just received FDA approval for cosmetic use in the United States, making it a viable option for patients seeking aesthetic enhancements. Its availability globally varies, with some regions having approved its use for cosmetic and medical applications. In the United States, LetYbo is typically administered by licensed healthcare professionals, including dermatologists, plastic surgeons, and certified injectors, ensuring safe and effective treatment outcomes.
LetYbo’s emergence underscores the ongoing pursuit of innovation in the quest for beauty and aesthetics, offering patients new possibilities. LETYBO is a promising addition to the arsenal of products available in the field of aesthetics and cosmetic medicine. Its unique properties and potential benefits make it an attractive option for patients looking to rejuvenate their appearance without surgery.
This is the latest toxin coming from Korean skincare. It is said to have a faster onset as little as 24 hours and lasts up to 4 months. This will be the 6th toxin to market starting with Botox Cosmetic, Xeomin, Dysport, Daxxify, and Jeuveau.
Top 11 Neurotoxins worldwide:
Botox (Allergan), Dysport (Galderma), Xeomin (Merz), Jeuveau (Evolus), Daxxify (Revance), Azzalure, Reloxin, Bocoture, PurTox, Neuronox and LetYbo.
Botox for Erectile Dysfunction
Publication year: 2022
Journal name: Journal of Sexual Medicine
The 2022 study published in the Journal of Sexual Medicine evaluates the use of Botulinum neurotoxin, specifically BoNT-A, as a treatment for erectile dysfunction (ED) in men who do not respond to traditional therapies, particularly phosphodiesterase type 5 inhibitors (PDE5i). ED is a common condition, affecting between 3% and 76. 5% of men globally, with the likelihood increasing with age. Beyond the physical implications, ED significantly impacts psychological well-being and interpersonal relationships, underscoring the need for effective interventions. The study's objective was to assess both the efficacy and safety of intracavernosal injections (ICI) of BoNT-A in men with ED who have not benefitted from conventional treatments.
The research followed a structured methodology, involving a prospective, double-blinded, randomized controlled trial with 70 male participants who had been refractory to PDE5i. These patients were randomly assigned to receive either 100 units of BoNT-A or saline solution as a control. Assessments were conducted through various measures, including the erection hardness score (EHS), peak systolic velocity (PSV), end-diastolic velocity (EDV), and the Sexual Health Inventory for Men (SHIM) questionnaire. Evaluations occurred at baseline and then again at 2, 6, and 12 weeks post-injection, with statistical analysis focused on mean comparisons, marking significance at a p-value of less than 0. 05. The results revealed that patients in the BoNT-A group experienced notable advancements in the primary outcome measures compared to controls.
Specifically, the EHS showed a statistically significant mean score increase. The PSV demonstrated a mean increase of p = 0. 005, while the EDV had favorable changes with a p-value of less than 0. 001. In terms of the SHIM scores, there was a significant rise recorded at both 6 and 12 weeks, peaking with a 5-point improvement from the baseline scores. It's important to note that, despite 18 patients reporting erections sufficient for penetration, only three were able to achieve vaginal intercourse. Interestingly, despite the presence of various comorbidities and known risk factors, these did not seem to significantly influence the treatment response.
In conclusion, the study indicates that intracavernosal administration of BoNT-A could be an effective alternative for managing ED in patients who do not respond to PDE5i therapies, showcasing both efficacy and a favorable safety profile. However, the transient nature of BoNT-A's effects indicates the potential need for repeated treatment sessions, similar to established injectable treatments like PGE1. The small sample size and single-center nature of the trial restrict its generalizability, and the lack of long-term follow-up data restricts insights into sustained efficacy and safety.
Going forward, further large-scale, multicentric trials would be beneficial to gain a deeper understanding of the long-term safety and optimal dosing strategies for BoNT-A in treating ED. Additionally, exploring the efficacy of combined treatments, integrating BoNT-A with currently available ED medications, could lead to improved clinical outcomes. From a clinical standpoint, these findings highlightBoNT-A's potential as a valid treatment option for men with ED, particularly those who have exhausted traditional avenues. Clinicians must carefully select patients, assessing individual health conditions and previous treatment responses, to effectively integrate this emerging therapy into their practices. This advancement in the treatment of ED could significantly enhance the therapeutic options available to practitioners, ultimately benefiting patients.